Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Pre-Mkt 03-19 04:37:46 EDT

2.47

-0.27

-9.85%

High2.76	Low2.45	Vol658.29K
Open2.72	D1 Closing2.74	Amplitude11.06%
Mkt Cap70.04M	Tradable Cap59.92M	Total Shares28.36M
T/O1.66M	T/O Rate2.71%	Tradable Shares24.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":2.47,"timestamp":1773864000000,"preClose":2.74,"halted":0,"volume":658290,"delay":0,"changeRate":-0.09854014598540146,"floatShares":24260500,"shares":28355300,"eps":-1.40396,"marketStatus":"Pre-Mkt","change":-0.27,"latestTime":"03-19 04:37:46 EDT","open":2.72,"high":2.755,"low":2.452,"amount":1659237.455514,"amplitude":0.110584,"askPrice":3,"askSize":500,"bidPrice":2.2,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.40396,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773927000000},"marketStatusCode":1,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":2.47,"postHourTrading":{"tag":"盘后","latestPrice":2.48,"preClose":2.47,"latestTime":"18:31 EDT","volume":776,"amount":1932.76,"timestamp":1773873102326,"change":0.01,"changeRate":0.004049,"amplitude":0.016194},"volumeRatio":1.6927234663230522,"impliedVol":1.3655,"impliedVolPercentile":0.732},"requestUrl":"/m/hq/s/ANVS/wiki","defaultTab":"wiki","newsList":[{"id":"2620826966","title":"Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620826966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620826966?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:30","pubTimestamp":1773858626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Warby Parker (WRBY) and Annovis Bio (ANVS) with bull...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-warby-parker-wrby-and-annovis-bio-anvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-warby-parker-wrby-and-annovis-bio-anvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBI","BK4200","LABU","HCSG","BK4137","BK4588","ANVS","BK4585","LU0128526141.USD","BK4581","XLV","LU0029874061.USD","WRBY"],"gpt_icon":0},{"id":"2619450352","title":"BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450352","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450352?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:38","pubTimestamp":1773661101,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial ResultsMarch 16 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS PROVIDES CORPORATE UPDATES AND REPORTS FISCAL YEAR 2025 FINAN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA6G3G39:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2619445037","title":"Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2619445037","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619445037?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:35","pubTimestamp":1773660920,"startTime":"0","endTime":"0","summary":"“The year 2025 was a landmark period for Annovis, one in which we took decisive steps toward bringing buntanetap to patients,” said Maria Maccecchi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-reports-fy25-eps-1-40-vs-2-31-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-reports-fy25-eps-1-40-vs-2-31-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"gpt_icon":0},{"id":"2619570494","title":"Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2619570494","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619570494?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:33","pubTimestamp":1773660798,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.34) by 13.7 percent. This is a 9.3 percent increase over losses of $(0.43) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51265214/annovis-bio-q4-eps-0-39-misses-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2619570634","title":"Annovis Bio Inc: Estimates That Its Current Cash and Cash Equivalents Will Enable It to Fund Its Operations Into Q3 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619570634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619570634?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA6G3G39:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2619457045","title":"Press Release: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457045?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660600,"startTime":"0","endTime":"0","summary":"In 2025, Annovis achieved a significant milestone in its clinical development program with the initiation of a pivotal Phase 3 clinical trial in early AD. The year was largely dedicated to the activation of clinical sites and the enrollment of participants across the United States. The Company also reported encouraging data from both its previous Alzheimer's and Parkinson's programs, demonstrating a potential disease-modifying signal for buntanetap through reductions in biomarkers of amyloid and tau pathology, neuroinflammation, and neurodegeneration. Building on this momentum, Annovis recently initiated an open-label extension  study in PD.\"The year 2025 was a landmark period for Annovis, one in which we took decisive steps toward bringing buntanetap to patients,\" said Maria Maccecchini, Ph.D., Founder and CEO of Annovis. \"We initiated our pivotal Phase 3 AD study and later launched an OLE PD study, both critical milestones on the path to an NDA submission. Throughout the year, we rem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","LU2242644610.SGD","LU2279858448.HKD","LU0455707207.USD","LU1235295612.USD","LU0315179316.USD","LU0370786039.SGD","LU0823397285.USD","LU1303224171.USD","LU1046422090.SGD","IE00B29SXG58.USD","LU0871576103.HKD","BK4139","LU0516423174.USD","LU0633140727.USD","PDDL","LU0051755006.USD","LU2211817866.USD","BK4588","LU0072462343.USD","LU0359202008.SGD","LU0594300419.USD","IE00B3M56506.USD","HK0000320264.USD","LU1171460220.USD","BK4535","HK0000320223.HKD","BK4220","BK4558","SG9999002562.SGD","LU1048596156.SGD","KPDD","LU0516423091.SGD","SG9999014674.SGD","LU1169590202.USD","LU0231483743.USD","LU0348805143.USD","LU0327786744.USD","LU1242518857.USD","LU0417516902.SGD","LU1868837722.USD","BK4023","IE00B0JY6N72.USD","LU0823039010.USD","LU1064131342.USD","BK4526","LU1981816686.USD","LU1880383366.USD","LU2257852520.SGD","LU0143863198.USD","LU1956131251.USD","BK4122","LU0052750758.USD","LU1323998911.USD","BK4585","LU0823426480.USD","LU1242518931.SGD","HK0000306701.USD","LU0516422366.SGD","LU1988902786.USD","LU0823426308.USD","LU1719994722.HKD","LU1770034418.SGD","LU1868838027.USD","LU0456846285.SGD","LU2264538146.SGD","LU0823413660.USD","LU0605514214.HKD","LU0516422440.USD","LU0823397103.USD","LU1769817096.USD","LU0737861772.HKD","LU2087589342.USD","LU0359201885.HKD","IE00BGV7N243.SGD","LU2399975544.HKD","BK4548","LU0531971595.HKD","LU0650527681.SGD","HK0000306685.HKD","LU2008162690.USD","LU1720050803.USD","LU0359201612.USD","LU0561508036.HKD","LU1880383440.USD","LU0589944569.HKD","LU1169589451.USD","LU0683595622.HKD","LU0878005551.USD","LU1251922891.USD","LU0633140560.USD","BK4531","LU1023057109.AUD","LU0588546209.SGD","LU0348825331.USD","BK4501","LU0502904849.HKD","LU0259732245.USD","LU0572944931.SGD","BK4504","LU0516422952.EUR","LU0235996351.USD","LU0823413587.USD","BK4505","LU0348827113.USD","LU0039217434.USD","LU1794554557.SGD","LU0117841782.USD","LU1769817179.HKD","LU0048580855.USD","BK4503","LU0329678337.USD","LU0594300179.USD","SG9999002828.SGD","BK4553","LU0049112450.USD","LU0329678170.USD","LU0708995583.HKD","LU0164865239.USD","LU0140636845.USD","LU1961090484.USD","LU0348788117.USD","IE0034224299.USD","LU2039709279.SGD","LU0821914370.USD","LU0210526637.USD","LU0979878070.USD","BK4110","LU0143863784.USD","BK4132","LU0047713382.USD","LU1808992512.USD","LU2177674079.SGD","LU1048588211.SGD","LU1868837565.USD","LU0456827905.SGD","LU0307460666.USD","LU0823038988.USD","SG9999002463.SGD","BK4509","LU0328353924.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2619914398","title":"Annovis Bio FY 2025 net loss widens 17% to USD 28.86 million, interest income rises 111% to USD 0.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619914398","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619914398?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:16","pubTimestamp":1773436598,"startTime":"0","endTime":"0","summary":"Annovis reported a FY 2025 net loss of USD 28.86 million, up 17% from the prior year. FY 2025 research and development expense rose 26% to USD 25.22 million, driven mainly by higher costs for patients in its Phase 3 Alzheimer’s trial and increased bioanalytical work. FY 2025 general and administrative expense fell 33% to USD 4.48 million, primarily due to lower stock-based compensation, stock listing and transfer fees, and corporate legal costs. FY 2025 interest income increased 111% to USD 0.7 million, reflecting higher cash and cash equivalents following a February 2025 public offering. Annovis ended FY 2025 with USD 19.5 million in cash and cash equivalents and said it expects this to fund operations into the third quarter of 2026, while noting it does not have sufficient capital to fund the next 12 months beyond the filing date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL12zxh5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2616400553","title":"Annovis Bio to Present Twice at AD/PD 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616400553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616400553?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542961,"startTime":"0","endTime":"0","summary":"Annovis Bio to Present Twice at AD/PD 2026 International Conference               Annovis Bio Inc. will attend the AD/PD 2026 International Conference, held March 17-21, 2026, in Copenhagen, Denmark, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1HS2WS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","NDAQ","LU2095319765.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","ANVS","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","BK4585","LU2210149790.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2613292091","title":"Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2613292091","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613292091?lang=en_us&edition=fundamental","pubTime":"2026-02-21 04:45","pubTimestamp":1771620328,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Annovis Bio. The associated price target is $8.00. Jason McCarthy has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/annovis-bio-advancing-phase-3-neurodegeneration-programs-create-attractive-risk‑reward-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/annovis-bio-advancing-phase-3-neurodegeneration-programs-create-attractive-risk‑reward-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"gpt_icon":0},{"id":"2610927693","title":"Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2610927693","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610927693?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:35","pubTimestamp":1770906929,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Annovis Bio ( ($ANVS) ). On February 12, 2026, Annovis Bio said an independent Data and Safety Monitoring Board...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-advances-alzheimers-phase-3-trial-after-safety-nod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-advances-alzheimers-phase-3-trial-after-safety-nod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2610992996","title":"Annovis Bio Inc - Dsmb Finds No Safety Concerns, Trial to Continue as Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610992996?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA3HJRSV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2610927854","title":"Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2610927854","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610927854?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb.  12, 2026  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237130/0/en/Annovis-Secures-DSMB-Approval-to-Advance-Pivotal-Phase-3-Trial-of-Buntanetap-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AD","PD","BK4132","LU1169590202.USD","LU1169589451.USD","BK4023","ANVS"],"gpt_icon":0},{"id":"2607072548","title":"Annovis Bio Hosts Regulation FD Investor Information Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2607072548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607072548?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:50","pubTimestamp":1769637041,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has shared an announcement. On January 28, 2026, Annovis Bio, Inc. held a webinar, supported by a prepared presentation tha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-hosts-regulation-fd-investor-information-webinar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-hosts-regulation-fd-investor-information-webinar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","III","BK4134","BK4139"],"gpt_icon":0},{"id":"2592184979","title":"Annovis Bio Launches 36-Month Study of Buntanetap in Parkinson's Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184979","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592184979?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:35","pubTimestamp":1766093715,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. announced plans to begin an Open-Label Extension  study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson's disease. The study aims to enroll 500 participants, including both previous Annovis clinical trial participants and patients who have been receiving deep brain stimulation  for at least 12 months. The study will monitor patients over 36 months and collect skin and plasma biomarkers to enhance understanding of disease progression. The announcement outlines future research; no specific scientific results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via Glob","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL46bhv0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","ANVS","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD","BK4139","IE00BKPKM429.USD","BK4112","LU0314104364.USD","SG9999014013.SGD","SG9999014005.SGD","LU2210150020.SGD","LU2095319765.USD","SG9999014039.USD"],"gpt_icon":0},{"id":"2592184980","title":"Annovis Bio Inc - to Begin Open-Label Extension Study in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592184980?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:35","pubTimestamp":1766093700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6M7P0P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2591847509","title":"Annovis Bio Inc. Hosts Corporate Update Webinar Featuring CEO Maria Maccecchini","url":"https://stock-news.laohu8.com/highlight/detail?id=2591847509","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591847509?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890032,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. will host a corporate update webinar on January 28, 2026, at 4:30 p.m. ET. The event will feature President and CEO Maria Maccecchini, Ph.D., who will provide an overview of the company's recent progress, ongoing clinical programs, and strategic direction. The webinar is open to shareholders, patients, investigators, and other interested parties, with a live Q&A session to follow the presentation. Participants are encouraged to submit questions in advance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1Tq6Wm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","ANVS","NDAQ","BK4139"],"gpt_icon":0},{"id":"2591982564","title":"Annovis to Host Corporate Update Webinar on January 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982564","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982564?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Dec.  16, 2025  (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neuro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206176/0/en/Annovis-to-Host-Corporate-Update-Webinar-on-January-28-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HST","LU1169590202.USD","BK4023","AD","ANVS","BK4181","BK4588","LU1169589451.USD","PD","BK4132","BK4585","BK4218"],"gpt_icon":0},{"id":"2590360322","title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360322","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590360322?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:05","pubTimestamp":1765242345,"startTime":"0","endTime":"0","summary":"Michael B. Hoffman, Director of Annovis Bio Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL4FctjJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2588904620","title":"Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588904620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588904620?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766846,"startTime":"0","endTime":"0","summary":"Annovis Bio Inc. will present at the 2025 Annual Meeting of the Parkinson Study Group, taking place from December 4-6, 2025, in San Diego, California. The company will showcase new data on buntanetap's effects in Parkinson's disease dementia patients, focusing on cognitive outcomes and biomarker improvements, with a poster guided tour led by President and CEO Maria Maccecchini scheduled for December 5 at 6:15 p.m. PST.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2hByHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","BK4112","BK4139","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD"],"gpt_icon":0},{"id":"2586410289","title":"Director Makes Bold Move with Major Annovis Bio Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2586410289","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586410289?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:11","pubTimestamp":1764123106,"startTime":"0","endTime":"0","summary":"New insider activity at Annovis Bio ( ($ANVS) ) has taken place on November 25, 2025. Director Michael B. Hoffman recently made a significant inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-annovis-bio-stock-purchase-insider-trading-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-annovis-bio-stock-purchase-insider-trading-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":0.0422},{"period":"3month","weight":-0.327},{"period":"6month","weight":0.0647},{"period":"1year","weight":0.3876},{"period":"ytd","weight":-0.2861}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.043323},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.134852},{"month":5,"riseRate":0.666667,"avgChangeRate":0.302491},{"month":6,"riseRate":0.5,"avgChangeRate":0.167707},{"month":7,"riseRate":0.666667,"avgChangeRate":0.098191},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070358},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction